Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population

Journal of Occupational and Environmental Medicine

Volumn 48, Issue 8, 2006, Pages 794-802

  Colice, G ^a   Wu, Eric Q ^b,c   Birnbaum, H ^b   Daher, M ^b   Marynchenko, M B ^b   Varghese, S ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b ANALYSIS GROUP   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR STIMULATING AGENT; METHYLXANTHINE DERIVATIVE;

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRACTICE GUIDELINE;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COSTS AND COST ANALYSIS; DISEASE MANAGEMENT; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PRIVATE SECTOR; REGRESSION ANALYSIS;

EID: 33747143724     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000229819.26852.0e     Document Type: Article

References (30)

1. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol. 2002;109:S482-489.
2. Self-reported asthma among high school students. MMWR Morb Mortal Wkly Rep. 2005;54:765-767.
3. Asthma prevalence and control characteristics by race/ethnicity - United States, 2002. MMWR Morb Mortal Wkly Rep. 2004;53:145-148.
4. American Lung Association Asthma in Adults Fact Sheet. American Lung Association; 2003.
5. American Lung Association Epidemiology & Statistics Unit. Trends in asthma morbidity and mortality. Available at: http://www.lungusa.org. Accessed May 2005.
6. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326:862-866.
7. Smith DH, Malone DC, Lawson KA, et al. Am J Respir Crit Care Med. 1997;156:787-793.
8. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. J Allergy Clin Immunol. 2001;107:3- 8.
9. Thomas M, Cleland J, Price D. Database studies in asthma pharmacoeconomics. Exp Opin Pharmacother. 2003;4:351-358.
10. Birnbaum HG, Berger WE, Greenberg PE, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol. 2002;109:264 -270.
11. Use of Appropriate Medications for People With Asthma. HEDIS 2005, vol 2. Technical Specifications. Washington, DC: National Committee for Quality Assurance; 2004:127-129.
12. Leidy NK, Paramore LC, Watrous M, et al. Development of an algorithm for estimating asthma severity from an administrative cost database. Value Health. 1999;2:394.
13. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Heart, Lung and Blood Institute, National Institutes of Health; 2002; Publication No 02-3659; Management Segment (Chapter 7). Updated 2004 from the 2003 document.
14. Cabana MD, Slish KK, Nan B, et al. Limits of the HEDIS criteria in determining asthma severity for children. Pediatrics. 2004;114:1049 -1055.
15. Berger WE, Legorreta AP, Blaiss MS, et al. The utility of the Health Plan Employer Data and Information set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol. 2004;93:538 -545.
16. Barnett A, Birnbaum H, Cremieux P, et al. The costs of cancer to a major employer in the United States: A case-control analysis. Am J Managed Care. 1990;6:1243-1251.
17. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13:1-7.
18. Goeree R, O'Brien BJ, Blackhouse G, et al. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry. 1999;44:455- 463.
19. Little R, Rubin D. Statistical Analysis With Missing Data. New York: John Wiley & Sons; 1987:62- 67.
20. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247-281.
21. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-295.
22. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1:54 -77.
23. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111:1212-1218.
24. Colice GL, Vanden Burgt J, Song J, et al. Categorizing asthma severity. Am J Respir Crit Care Med. 1999;160:1962-1967.
25. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States. Am J Respir Crit Care Med. 2002;166:1044 -1049.
26. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity. Eur Respir J. 2002;19:61- 67.
27. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12:1322-1326.
28. Sin DD, Man SFP. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med. 2002;162:1591-1595.
29. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887- 891.
30. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114:1288 -1293.